JP5160534B2 - 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物 - Google Patents

低免疫原性および長時間循環性タンパク質−脂質複合体の組成物 Download PDF

Info

Publication number
JP5160534B2
JP5160534B2 JP2009503092A JP2009503092A JP5160534B2 JP 5160534 B2 JP5160534 B2 JP 5160534B2 JP 2009503092 A JP2009503092 A JP 2009503092A JP 2009503092 A JP2009503092 A JP 2009503092A JP 5160534 B2 JP5160534 B2 JP 5160534B2
Authority
JP
Japan
Prior art keywords
lipid
protein
factor
composition
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009503092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532371A (ja
JP2009532371A5 (enExample
Inventor
バルー‐アイヤー，サティ，ヴィー．
ストラウビンガー，ロバート，エム．
ミクレア，ラズヴァン
ペング，アーロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of JP2009532371A publication Critical patent/JP2009532371A/ja
Publication of JP2009532371A5 publication Critical patent/JP2009532371A5/ja
Application granted granted Critical
Publication of JP5160534B2 publication Critical patent/JP5160534B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2009503092A 2006-03-30 2007-03-30 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物 Expired - Fee Related JP5160534B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US78741106P 2006-03-30 2006-03-30
US78758606P 2006-03-30 2006-03-30
US60/787,411 2006-03-30
US60/787,586 2006-03-30
US86506206P 2006-11-09 2006-11-09
US60/865,062 2006-11-09
US87017706P 2006-12-15 2006-12-15
US60/870,177 2006-12-15
PCT/US2007/008311 WO2007117469A2 (en) 2006-03-30 2007-03-30 Compositions of less immunogenic and long-circulating protein-lipid complexes

Publications (3)

Publication Number Publication Date
JP2009532371A JP2009532371A (ja) 2009-09-10
JP2009532371A5 JP2009532371A5 (enExample) 2010-05-13
JP5160534B2 true JP5160534B2 (ja) 2013-03-13

Family

ID=38581584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503092A Expired - Fee Related JP5160534B2 (ja) 2006-03-30 2007-03-30 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物

Country Status (7)

Country Link
US (2) US7875289B2 (enExample)
EP (1) EP2007357B1 (enExample)
JP (1) JP5160534B2 (enExample)
AU (1) AU2007235463B2 (enExample)
CA (1) CA2660310C (enExample)
NZ (1) NZ572308A (enExample)
WO (1) WO2007117469A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US20120164189A1 (en) * 2009-07-07 2012-06-28 Balu-Iyer Sathy V Lipidic Compositions for Induction of Immune Tolerance
US10617640B2 (en) 2009-07-07 2020-04-14 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US10064922B2 (en) 2011-10-06 2018-09-04 The Research Foundation For The State University Of New York Compositions and methods for immune tolerance induction
EA201791738A1 (ru) 2012-05-09 2018-03-30 Вестерн Юниверсити Оф Хелт Сайенсиз Пролипосомальные композиции тестостерона
EP2968474A4 (en) * 2013-03-13 2016-11-23 Stemetrix Inc SKIN COMPOSITIONS AND USES
WO2015048145A1 (en) 2013-09-24 2015-04-02 The Research Foundation For The State University Of New York Compositions and methods for reducing antigen-specific immunogenicity
US20230255888A1 (en) * 2020-07-01 2023-08-17 The Research Foundation For The State University Of New York Method for preparation of liposomes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127502A (en) * 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4795806A (en) * 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
KR100217826B1 (ko) * 1992-04-10 1999-09-01 나까도미 히로다카 리포솜조성물
DE4416180C2 (de) * 1994-05-06 1997-08-14 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
CA2181390C (en) 1995-07-18 2001-04-24 Pankaj Modi Phospholipid formulations
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
WO1998048837A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
MXPA00010241A (es) * 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
EP1443900B1 (en) * 2001-11-13 2012-05-23 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
US20040229793A1 (en) * 2003-02-05 2004-11-18 Balasubramanian Sathyamangalam V. Compositions and methods for less immunogenic protein formulations
US7351688B2 (en) 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
TW201424770A (zh) * 2003-02-14 2014-07-01 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
WO2006055352A2 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
JP2008544990A (ja) 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes

Also Published As

Publication number Publication date
US20070274980A1 (en) 2007-11-29
WO2007117469A2 (en) 2007-10-18
JP2009532371A (ja) 2009-09-10
AU2007235463A1 (en) 2007-10-18
CA2660310C (en) 2015-04-21
EP2007357A2 (en) 2008-12-31
US20110123625A1 (en) 2011-05-26
CA2660310A1 (en) 2007-10-18
AU2007235463B2 (en) 2012-11-22
EP2007357A4 (en) 2013-07-17
WO2007117469A3 (en) 2008-07-03
US7875289B2 (en) 2011-01-25
EP2007357B1 (en) 2016-11-09
NZ572308A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
JP5160534B2 (ja) 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物
JP3051650B2 (ja) 血液凝固疾患の治療のための安定な調製物
US20120164189A1 (en) Lipidic Compositions for Induction of Immune Tolerance
US7875288B2 (en) Method for treating blood coagulation disorders
Ramani et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A
EP1898939A2 (en) Compositions and methods for less immunogenic pr0tein-lip1d complexes
US20240366732A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US7351688B2 (en) Compositions and methods for less immunogenic protein formulations
US10064922B2 (en) Compositions and methods for immune tolerance induction
US11484499B2 (en) Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors
WO2007123691A2 (en) Method for treating blood coagulation disorders
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
Ramani et al. Preclinical Evaluation of PEGylated Liposomal-Recombinant Human FVIII in a Murine Model of Hemophilia A
MX2008000223A (en) Compositions and methods for less immunogenic pr0tein-lip1d complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120725

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121212

R150 Certificate of patent or registration of utility model

Ref document number: 5160534

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151221

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees